Accéder au contenu
Merck
Toutes les photos(1)

Documents

SML3967

Sigma-Aldrich

Levonorgestrel

≥98% (HPLC)

Synonyme(s) :

(17α)-13-Ethyl-17-hydroxy-18,19-dinorpregn-4-en-20-yn-3-one, 13-Ethyl-17-ethynyl-17β-hydroxy-4-gonen-3-one, 13-Ethyl-17-hydroxy-18,19-dinor-17α-pregn-4-en-20-yn-3-one, D(−)-Norgestrel, D-Norgestrel, LNG

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C21H28O2
Numéro CAS:
797-63-7
Poids moléculaire :
312.45
Numéro MDL:
MFCD01546387
Code UNSPSC :
12352200
Nomenclature NACRES :
NA.77

Niveau de qualité

100

Pureté

≥98% (HPLC)

Forme

powder

Activité optique

[α]/D -28 to -36° (C= 1.0g/100 ml in CDCl3)

Couleur

white to beige

Solubilité

DMSO: 2 mg/mL, clear

Température de stockage

-10 to -25°C

Actions biochimiques/physiologiques

Orally bioavailable synthetic progestational agent that reversibly binds to progesterone receptors with high-affinity in the hypothalamus, pituitary gland, and uterus.

Levonorgestrel (D-Norgestrel) is an orally bioavailable synthetic progestational agent that reversibly binds to progesterone receptors with high-affinity in the hypothalamus, pituitary gland, and uterus. Levonorgestrel inhibits the release of gonadotropin-releasing hormone (GnRH), luteinizing hormone (LH), and follicle-stimulating hormone (FSH). D(−)-Norgestrel prevents fertilization by altering cervical mucus consistency, and interfering with the endometrial lining, making it less receptive to implantation. Levonorgestrel (LNG) can be used alone or in combination with estrogen during hormone replacement therapy.

Pictogrammes

Health hazard
GHS08

Mention d'avertissement

Danger

Mentions de danger

H351,H360D,H362

Classification des risques

Carc. 2 - Lact. - Repr. 1A

Code de la classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

K Fotherby
Contraception, 54(2), 59-69 (1996-08-01)
The concept of bioavailability is discussed with particular references to the sex steroids. Problems encountered in the measurement of bioavailability of these steroids and the various factors that may affect their bioavailability are briefly described. Information regarding the bioavailability of
Ioannis D Gallos et al.
American journal of obstetrics and gynecology, 203(6), 547-547 (2010-10-12)
To conduct a systematic review and metaanalysis of studies evaluating the regression rate of endometrial hyperplasia with oral progestogens and levonorgestrel-releasing intrauterine system. Searches were conducted on Medline, Embase, Cochrane Library, and Web of Science, and reference lists of relevant
Raymond Hang Wun Li et al.
Lancet (London, England), 402(10405), 851-858 (2023-08-20)
Levonorgestrel, a standard drug for emergency contraception (EC), is not effective if administered post-ovulation. A cyclo-oxygenase inhibitor could contribute synergistic effects. We investigated whether a single 40 mg oral dose of piroxicam as co-treatment with levonorgestrel improved emergency contraceptive efficacy.

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique